Research ArticleOncology

Long-Term Effects of Radioiodine Treatment on Salivary Gland Function in Adult Survivors of Pediatric Differentiated Thyroid Carcinoma

Tharsana Selvakumar, Marloes Nies, Mariëlle S. Klein Hesselink, Adrienne H. Brouwers, Anouk N.A. van der Horst-Schrivers, Esther N. Klein Hesselink, Wim J.E. Tissing, Arjan Vissink and Thera P. Links; on behalf of the Dutch Pediatric Thyroid Cancer Study Consortium
Journal of Nuclear Medicine February 2019, 60 (2) 172-177; DOI: https://doi.org/10.2967/jnumed.118.212449

Article Figures & Data

Figures

Tables

  • TABLE 1

    Baseline Characteristics of the 65 Included Patients at Diagnosis

    CharacteristicData
    Sex (n)
     Female56 (86.2)
     Male9 (13.8)
    Age at diagnosis
     Median (y)15
     IQR (y)13–17
     <12 (n)7 (10.8)
     ≥12 (n)58 (89.2)
    Histology (n)
     PTC53 (81.5)
     FTC12 (18.5)
    Lymph node metastasis (n)
     Yes39 (60.0)
     No16 (24.6)
     Unknown10 (15.4)
    TNM classification (n)
     T stage
      T122 (33.8)
      T218 (27.7)
      T39 (13.8)
      T44 (6.2)
      Tx12 (18.5)
     N stage
      N029 (44.6)
      N130 (46.2)
      Nx6 (9.2)
     M stage
      M052 (80.0)
      M16 (9.2)
      Mx7 (10.8)
     Stage I52 (80.0)
     Stage II6 (9.2)
     Stage unknown7 (10.8)

    • PTC = papillary thyroid cancer; FTC = follicular thyroid cancer.

    • Data are n followed by percentage in parentheses, except for age.

  • TABLE 2

    Radioiodine Treatment Characteristics

    CharacteristicNo. of patientsMedianIQR
    No. of 131I treatments11–3
    Cumulative 131I activity per 131I treatment (GBq)
     Only ablation34 (52.3%)3.71.85–5.85
     Repeated31 (47.7%)12.957.92–18.50
      213 (20.0%)5.553.70–5.81
      37 (10.8%)5.553.70–5.70
      44 (6.2%)5.553.70–5.62
      55 (7.7%)6.115.55–7.59
      62 (3.1%)6.44*
    Cumulative 131I activity of all patients (GBq)65 (100%)5.882.92–12.95
    Cumulative 131I activity (GBq) per TNM stage
     Stage I52 (80%)5.712.78–11.75
     Stage II6 (9.2%)14.4311.24–19.14
     Stage unknown7 (10.8%)5.712.18–8.33

    • ↵* IQR could not be estimated.

  • TABLE 3

    Sialochemistry Results

    Sialochemistry compositionMedianIQR
    UWS (n = 59)*
    Sodium (mmol/L)5.063.11–7.78
    Potassium (mmol/L)16.4
    Chloride (mmol/L)15.012.3–17.0
    Total protein (g/L)0.260.21–0.38
    Total protein (mg/min)0.070.05–0.12
    Amylase (103U/L)55.532.2–95.1
    Amylase (U/min)13.68.17–24.5
    SWS (n = 62)†
    Sodium (mmol/L)8.405.32–12.1
    Potassium (mmol/L)19.515.9–23.1
    Chloride (mmol/L)15.013.0–17.3
    Total protein (g/L)0.260.19–0.36
    Total protein (mg/min)0.220.15–0.30
    Amylase (103U/L)68.545.7–103
    Amylase (U/min)53.31.4–94.4

    • ↵* Chloride and total protein levels were analyzed in 60 patient samples.

    • ↵† Sodium levels were analyzed in 61 patient samples.

  • TABLE 4

    Classification XI Scores

    ClassificationTotal XI scoreNo. of patients*
    No to mild complaints11–2339 (62.9%)
    Moderate to severe complaints24–3922 (35.5%)
    Severe to extreme complaints40–551 (1.6%)

Additional Files

Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools
Bookmark this article

Jump to section

Keywords